Investigation of Corrosion Mechanism of Ribbed Mild Steel Bars Coated with Magnesium Potassium Phosphate Cement Paste

This Study Investigated the Anti-Corrosion Performance of Magnesium Potassium Phosphate Cement (MKPC) Paste Applied to the Surface of Ribbed Mild Steel Bars – Which Was Exposed to Simulated Accelerated Corrosive Environment. Four Electrochemical Approaches Were Used Including Open-Circuit Potential (OCP), Electrochemical Impedance Spectroscope (EIS), Polarization Resistance (PR) and Potentiodynamic Polarization (PDP) over a Period of 5376 H (224 Days). Moreover, Visual Inspection, Optical Microscope, and Scanning Electron Microscopy (SEM) with Energy Dispersive Spectroscopy (EDS) Were Used to Assess the Extent of Corrosion on the Samples. to Understand the Mechanism of Corrosion Protection of the Coating System, X-Ray Photoelectron Spectroscopy (XPS) Was Employed to Characterize the Chemical Groups on the Surface of Mild Steel, and the Chemical Changes in the Coating Layer Were Characterized using Thermogravimetric/differential Thermal Analysis (TG/DTA) and X-Ray Diffraction (XRD). the MKPC Paste Coated Bars Were Compared with Not Only Uncoated Bars, But Also Bars Coated with Ordinary Portland Cement (OPC) that is Known to Passivate Steel Due to its High Alkalinity. Results Indicated that MKPC Paste Coating Layer Could Effectively Protect the Ribbed Mild Steel Bars, and its Protectiveness Significantly Surpassed that of OPC. Both the De-Passivation Effects of Chloride Ions and Carbonation of the OPC Resulted in Relatively Severe Corrosion of the OPC Coated Bars during the Long Exposure Duration; While the Anti-Corrosion Merit of the MKPC Paste Coating Layer Could Be Attribute to a Double-Protection System– the Dense Microstructure of MKPC and the Formation of an Iron (III) Phosphate Passivation Layer between the Substrate Steel and the MKPC Paste Coating Layer

Blind Beamforming for Intelligent Reflecting Surface in Fading Channels without CSI

This paper discusses how to optimize the phase shifts of intelligent reflecting surface (IRS) to combat channel fading without any channel state information (CSI), namely blind beamforming. Differing from most previous works based on a two-stage paradigm of first estimating channels and then optimizing phase shifts, our approach is completely data-driven, only requiring a dataset of the received signal power at the user terminal. Thus, our method does not incur extra overhead costs for channel estimation, and does not entail collaboration from service provider, either. The main idea is to choose phase shifts at random and use the corresponding conditional sample mean of the received signal power to extract the main features of the wireless environment. This blind beamforming approach guarantees an $N^2$ boost of signal-to-noise ratio (SNR), where $N$ is the number of reflective elements (REs) of IRS, regardless of whether the direct channel is line-of-sight (LoS) or not. Moreover, blind beamforming is extended to a double-IRS system with provable performance. Finally, prototype tests show that the proposed blind beamforming method can be readily incorporated into the existing communication systems in the real world; simulation tests further show that it works for a variety of fading channel models.Comment: 14 pages, 14 figure

Cache attack on MISTY1

Side-channel attacks exploit information from physical implementations of cryptographic systems. Cache attacks have improved at recovering information by combining observations of the victim\u27s cache access and knowledge of the cipher’s structure. Cache attacks have been implemented for most Feistel- and SPN-structured block cipher algorithms, but the security of algorithms for special structures has seen little attention. We perform a Flush+Reload attack on MISTY1, a class of block cipher with a recursive structure. The function is performed before the plaintext input S-box and after the ciphertext output S-box, making it difficult to attack the first and last rounds. However, the key scheduling part of MISTY1 leaks many bits of the key, which, together with the leakage of partial bits of the round key during encryption, is sufficient to recover it. We design an algorithm that can recover the MISTY1 128-bit key after observing encryption one time, and then use leakage during encryption to reduce its complexity. We experiment on 32- and 64-byte cache line environments. An adversary need observe as little as 5 encryptions to recover the 128-bit key in 0.035 second in the first case, and 10 encryptions to recover the key in 2.1 hours in the second case

Factors associated with psychological insulin resistance among patients with type 2 diabetes in China

ObjectiveThe aim of this study was to understand the psychological insulin resistance status among Chinese patients with type 2 diabetes and investigate its associated factors in these patients.MethodsA multi-stage stratified random sampling was performed to randomly select patients with type 2 diabetes from the eastern, central, and western regions in Shandong Province, China, and 660 valid questionnaires were collected. Psychological insulin resistance was assessed by the scale of My Opinion on Insulin (MOI). Factors associated with psychological insulin resistance were examined in a binary logistic model.ResultsFour-fifths of the patients with type 2 diabetes (82.1%) had psychological insulin resistance. Being female (OR = 1.770, 95% CI: 1.063–2.950, p < 0.05), having a monthly income of greater than 4,000 Renminbi (approximately $1,540) (OR = 0.444, 95% CI: 0.216–0.915, p < 0.05), living with type 2 diabetes for 11 years or more (OR = 0.387, 95% CI: 0.238–0.630, p < 0.05), self-rated poor health (OR = 1.706, 95% CI: 1.092–2.664, p < 0.05), and moderate discrimination against type 2 diabetes (OR = 1.924, 95% CI: 1.166–3.175, p < 0.05) were associated with psychological insulin resistance.ConclusionsThe prevalence of psychological insulin resistance among Chinese patients with type 2 diabetes is relatively high. Approaches are needed to address the issue of psychological insulin resistance of type 2 diabetes

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China

ImportanceBoth pembrolizumab and sintilimab have been approved by the Chinese State Drug Administration (NMPA) for the first-line treatment of patients with advanced squamous lung cancer. The differences of the two drugs in efficacy and safety are unclear.ObjectivesTo compare the real-world efficacy and safety of first-line treatments in patients with advanced squamous lung cancer.Materials and methodsThis was a retrospective review of patients with advanced squamous carcinoma who received sintilimab or pembrolizumab in combination with chemotherapy as first-line therapy between June 2018 and April 2022 in the Chinese PLA Hospital. The primary objective was to compare the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) between the two groups. Secondary objectives were to compare the disease control rate (DCR) and to analyze adverse events (AEs) between the two groups.ResultsA total of 164 patients were enrolled, including 63 patients (38.4%) in the sintilimab-combined chemotherapy group and 101 patients (61.6%) in the pembrolizumab-combined chemotherapy group. The ORR was 65.10% in the sintilimab group and 61.40% in the pembrolizumab group (P=0.634). The DCR was 92.10% and 92.10% in the sintilimab and pembrolizumab groups, respectively (P=0.991). The median PFS was 22.2 months for patients treated with sintilimab group compared with 16.5 months for patients treated with pembrolizumab group[hazard ratio (HR) = 0.743; 95% confidence interval (CI): 0.479-1.152; P = 0.599]. Patients treated with pembrolizumab did not achieve a median OS, and patients treated with sintilimab had a median OS of 30.7 months. In the sintilimab group, the incidence of all treatment-related adverse events (TRAEs) was 92.1% (58/63), and the incidence of grade 3-4 TRAEs of 42.9% (27/63). In the pembrolizumab group, the incidence of all TRAEs was 90.1% (91/101), and the incidence of grade 3-4 TRAEs was 37.6% (38/101).ConclusionIn the clinical treatment of Chinese patients with advanced squamous lung cancer, first-line treatment with sintilimab in combination with chemotherapy provided similar efficacy to pembrolizumab in combination with chemotherapy, and the treatment-related adverse effect profiles were comparable between the two groups, including similar rates of grade 3-4 and all adverse events

The dynamic conformational landscape of the protein methyltransferase SETD8

Elucidating the conformational heterogeneity of proteins is essential for understanding protein function and developing exogenous ligands. With the rapid development of experimental and computational methods, it is of great interest to integrate these approaches to illuminate the conformational landscapes of target proteins. SETD8 is a protein lysine methyltransferase (PKMT), which functions in vivo via the methylation of histone and nonhistone targets. Utilizing covalent inhibitors and depleting native ligands to trap hidden conformational states, we obtained diverse X-ray structures of SETD8. These structures were used to seed distributed atomistic molecular dynamics simulations that generated a total of six milliseconds of trajectory data. Markov state models, built via an automated machine learning approach and corroborated experimentally, reveal how slow conformational motions and conformational states are relevant to catalysis. These findings provide molecular insight on enzymatic catalysis and allosteric mechanisms of a PKMT via its detailed conformational landscape

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/refractory mature Bcell tumors. Dose escalation followed a 3+3 design; patients received oral sovleplenib (200-800 mg once daily [q.d.] or 200 mg twice daily [b.i.d.], 28-day cycles). During dose expansion, patients were enrolled into four cohorts per lymphoma classification and treated at the recommended phase 2 dose (RP2D). Overall, 134 Chinese patients were enrolled (dose escalation, n=27; dose expansion, n=107). Five patients experienced dose-limiting toxicities: one each of amylase increased (200 mg q.d.), febrile neutropenia (800 mg q.d), renal failure (800 mg q.d.), hyperuricemia and blood creatine phosphokinase increased (200 mg b.i.d.) and blood bilirubin increased and pneumonia (200 mg b.i.d.). RP2D was determined as 600 mg (>65 kg) or 400 mg (≤65 kg) q.d. The primary efficacy end point of independent review committee–assessed objective response rate in indolent B-cell lymphoma was 50.8% (95% CI, 37.5–64.1) in 59 evaluable patients at RP2D (follicular lymphoma: 60.5%, marginal zone lymphoma: 28.6%, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, 0%). The most common (≥10% patients) grade ≥3 treatment-related adverse events in the doseexpansion phase were decreased neutrophil count (29.9%), pneumonia (12.1%) and decreased white blood cell count (11.2%). Pharmacokinetic exposures increased doseproportionally with ascending dose levels from 200–800 mg, without observed saturation. Sovleplenib showed antitumor activity in relapsed/refractory B-cell lymphoma with acceptable safety. Further studies are warranted

The global catalogue of microorganisms 10K type strain sequencing project: closing the genomic gaps for the validly published prokaryotic and fungi species

Genomic information is essential for taxonomic, phylogenetic and functional studies to comprehensively decipher the characteristics of microorganisms, to explore microbiomes through metagenomics, and to answer fundamental questions of nature and human life. However, large gaps remain in the available genomic sequencing information published for bacterial and archaeal species, and the gaps are even larger for fungal type strains. The Global Catalogue of Microorganisms (GCM) leads an internationally coordinated effort to sequence type strains and close gaps in the genomic maps of microbes. Hence, the GCM aims to promote research by deep-mining genomic data.This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (grant XDA19050301), the Bureau of International Cooperation of the Chinese Academy of Sciences (grants 153211KYSB20160029 and 153211KYSB20150010), the National Key Research Program of China (grants 2017YFC1201202, 2016YFC1201303, and 2016YFC0901702), the 13th Five-year Informatization Plan of the Chinese Academy of Sciences (grant XXH13506), and the National Science Foundation for Young Scientists of China (grant 31701157).info:eu-repo/semantics/publishedVersio

Measurement of the top quark forward-backward production asymmetry and the anomalous chromoelectric and chromomagnetic moments in pp collisions at √s = 13 TeV

Abstract The parton-level top quark (t) forward-backward asymmetry and the anomalous chromoelectric (d̂ t) and chromomagnetic (μ̂ t) moments have been measured using LHC pp collisions at a center-of-mass energy of 13 TeV, collected in the CMS detector in a data sample corresponding to an integrated luminosity of 35.9 fb−1. The linearized variable AFB(1) is used to approximate the asymmetry. Candidate t t ¯ events decaying to a muon or electron and jets in final states with low and high Lorentz boosts are selected and reconstructed using a fit of the kinematic distributions of the decay products to those expected for t t ¯ final states. The values found for the parameters are AFB(1)=0.048−0.087+0.095(stat)−0.029+0.020(syst),μ̂t=−0.024−0.009+0.013(stat)−0.011+0.016(syst), and a limit is placed on the magnitude of | d̂ t| < 0.03 at 95% confidence level. [Figure not available: see fulltext.